Exiqon
Home Search Contact Print
0 items in basket0
Sign In
 
 
Products Services Applications Resource Center Ordering About Exiqon
microRNA Research
lncRNA Research
mRNA Research
DNA Research
Custom Oligos
Other Reagents
RNA Isolation
Sequencing
Microarray Analysis
Real-time PCR
Northern Blotting
In Situ Hybridization
Functional Analysis
RNA Preparation
Sequencing
Microarray analysis
Real-time PCR
In Situ Hybridization
Antisense
RNA Preparation
Sequencing
Microarray analysis
Real-time PCR
In Situ Hybridization
Antisense
SNP Detection
Sequencing
Microarray Analysis
In Situ Hybridization
LNA Phosphoramidites
A2 Quencher
RNA Isolation Services
microRNA Array Services
microRNA PCR Services
Sequencing Services
microRNA ISH Services
Custom Pharma Service
Isolation
Microarray Analysis
Northern Blotting
Real-time PCR
In Situ Hybridization
Functional Analysis
SNP Detection
RNA
microRNA
RNA
DNA
microRNA
microRNA
mRNA
microRNA
Other RNAs
DNA
microRNA
RNA
DNA
microRNA Resources
mRNA and lncRNA Resources
Documents
Reading rooms
Technology
Oligo design tools
Movies
microRNA
Research Guide
Reading rooms
Application Stories
Bioinformatics and data analysis
What are lncRNAs?
Application Stories
Bioinformatics
Oligo modifications
LNA™
AQ-link
Order microRNA products
Order custom oligos
Distributors
Global Service Providers
General Information
Contact
News
Company profile
History
Management
Board of Directors
Awards & Partnerships
Newsletter
Career
Sign up to Newsletter
Newsletter Back Issues
 

Custom microRNA Inhibitors

LNA™-enhanced microRNA inhibitors, designed to specifically target your microRNA or other type of short ncRNAs not in miRBase.

  • Custom designed antisense sterical blockers of microRNA and other short ncRNAs not in miRBase
  • Tm-normalization with LNA™ technology ensures efficacy with even AT-rich microRNAs
  • Success even with hard-to-transfect cell lines with our exceptionally potent Power inhibitors that can be added directly to cell cultures without transfection reagents
  • Superior specificity and biological stability for long lasting antisense activity
  • End-labeling option for easy control of transfection efficiency
  • Available in 1 nmol, 5 nmol and 15 nmol quantities

Features

Custom miRCURY LNA™ microRNA Inhibitors and Power Inhibitors are available for specific knockdown of microRNAs or other short ncRNA sequences not in miRBase. These microRNA inhibitors are designed by our technical support scientist applying the same design rules used with our pre-designed microRNA Inhibitors.

A choice of two different product categories is offered in three different amounts (1 nmol, 5 nmol and 15 nmol) and with 6-FAM fluorescent end labels:

  • Custom miRCURY LNA™ microRNA Inhibitors

    Custom designed LNA™-enhanced microRNA inhibitors. These DNA/LNA™ mixmer antisense oligonucleotides have normal phosphodiester nucleotide bonds.

  • Custom miRCURY LNA™ microRNA Power Inhibitors

    Custom Power inhibitors have a fully phosphorothioate (PS) modified backbone which makes them highly resistant to enzymatic degradation. As a result they have superior potency and prolonged stability. In fact with many cell lines efficient microRNA inhibition can be achieved by adding Power inhibitors directly to the cell culture medium without transfection reagent thereby removing an important source of side effects unrelated to antisense activity. In all other respects this class of inhibitors is identical to our regular line of microRNA inhibitors.
In addition we can offer inhibitors with a wide variety of chemical modifications (learn more about our modifications).

All microRNA inhibitors are as a mininum desalted and delivered dried down in tubes, but we also offer HPLC purification followed by Na+ salt exchange if higher purity is required. Once dissolved, the oligonucleotides are ready for use.


Design

The sequences of the microRNA inhibitors and their LNA™ spiking patterns are carefully designed to ensure Tm normalization around an optimal temperature. As a result our inhibitors have uniform high potency regardless of the GC content of their microRNA targets.

The miRCURY LNA™ microRNA Power Inhibitors have phosphorothioate (PS) modified backbones that dramatically improve their biological stability. We therefore recommend these inhibitors in difficult applications where:

  • the transfection efficiency is limiting (primary cells, cells growing in suspension)
  • the microRNA target is highly expressed
  • the phenotypic readout that takes place >72 h after transfection (cell differentiation)
  • regular microRNA inhibitors fail
  • inhibitors are added directly to the cell culture without the use of transfection reagents
Note: Power Inhibitors are not recommended for use with cells or cell lines derived from muscle or the central nervous system (CNS). These cell types are known to be particularly sensitive to sequence-dependent toxicity of phosphorothioate-modified oligonucleotides.


Application

Our miRCURY LNA™ microRNA Inhibitors are ideal for use as specific suppressors of microRNA activity. Observing the effects of miRNA inhibition is an effective approach for the study of microRNA function in cellular processes and pathological pathways and microRNA regulation of gene expression including identification and validation of specific microRNA targets.

Before submitting your order, please check if a pre-designed microRNA inhibitor targeting your sequence is available . Pre-designed miRCURY LNA™ microRNA microRNA Inhibitors and Power Inhibitors are available for all microRNA sequences annotated in miRBase (v.20.0).

Magali Taulan

Development of antisense therapy for cystic fibrosis


"In our hands, in addition to high affinity, LNA™ antisense oligonucleotides display excellent activity upon simple addition to the cell culture – without the need for transfection reagents – which is great advantage when working with primary cell cultures."

Dr. Magali Taulan is an associate professor at the University of Montpellier in France. Her lab has been using LNA™ antisense oligonucleotides that interfere with microRNAs to better understanding how expression of the gene (CFTR) is regulated. As a result, the study potentially identify new targets for treatment of CF.

Read full story...

Kiran Kumar Bali

microRNAs in pain


"I recommend Exiqon's miRNA inhibitors mainly because of their specificity and less off-target effects. Customer friendly handling of orders and providing useful discussions with experienced scientists is another reason for my recommendation."

Dr. Kiran Kumar Bali is a postdoc in Prof. Rohini Kuner's lab at the University Clinic Heidelberg in Germany. He has been using microRNA inhibitors in vivo to study microRNAs involved in chronic pain.

Read full story...

Virgine Mattot

MicroRNA function in endothelial cells


"Target Site Blockers are efficient tools to demonstrate the specific involvement of putative microRNA targets in the function played by this microRNA. The use of LNA™ allows the design of short oligonucleotides that are very specific and easy to work with."

Dr. Mattot studies the roles played by microRNAs in endothelial cells during physiological and pathological processes such as angiogenesis or endothelium activation. The fact that her microRNA of interest had a predicted target gene which was previously uncharacterized was a major challenge. However through the use of specific target site blockers, it was possible to demonstrate that this unknown gene was associated with the phenotype observed when the microRNA was inhibited in endothelial cells.

Read full story...

Jan-Wilhelm Kornfeld

microRNA and diabetes


"The rapid generation and delivery of LNA™ microRNA inhibitors allowed for the quick execution of in vivo experiments and offered an attractive alternative to the generation of conventional microRNA knockout models. The addition, the LNA™ inhibitors are highly effective."

Dr. Jan-Wilhelm Kornfeld works in the lab of Prof. Jens C. Brüning in the Department of Mouse Genetics and Metabolism at the University of Cologne and the Max-Planck-Institute for Neurological Research (MPI-nF). Their work using in vivo LNA™ microRNA inhibitors towards miR-802 in mice demonstrates the great future potential for oligonucleotide-based therapeutics for this complex disease.

Read full story...

Stefanie Dimmeler

MicroRNAs in heart disease


"The LNA™-inhibitors from Exiqon just work."

Stefanie Dimmeler, Professor and group leader, and Reinier Boon, Post Doctoral researcher, work in the Institute for Cardiovascular Regeneration at the Goethe University Frankfurt, Germany. Here they study the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new therapies to improve treatment of cardiovascular diseases.

Read full story...

David C. Henshall

MicroRNAs in epilepsy


"For us the main benefits of Exiqon’s microRNA inhibitors have been potency and high stability."

Eva M. Jimenez-Mateos and David C. Henshall work at the Centre for the Study of Neurological Disorders at the Royal College of Surgeons in Ireland. Here, they study how microRNAs influence epilepsy. A main challenge in the project was finding the optimal dose of inhibitor and scramble control to get specific inhibition and avoid off-target effects.

Read full story...

Holger Willenbring

The role of miR-21 in liver regeneration


Holger Willenbring, Associate professor and Raymond Ng, PhD student, from Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research Department of Surgery, Division of Transplantation at the University of California San Francisco study many aspects of liver regeneration. They have been using Exiqon array services and miRCURY LNA™ microRNA in vivo inhibitors to study the role of miRNAs in this process.

Read full story...

Xavier Gidrol

High content microRNA inhibitor screening with cell arrays


"...thanks to the LNA™ microRNA inhibitor screen, we have discovered several new miRNAs playing a major role in the regulation of the proliferation/differentiation balance in prostate cells."

Dr. Xavier Gidrol directs the Biomics Laboratory at the Institute of Life Science Research and Technologies in Grenoble, France. They use microfluidics, micromanufacturing and MEMS to study the impact of genetic and micro-environmental determinants on carcinogenesis, at the scale of a few or even single cells. Xavier has used minute cell microarrays to perform high throughput and high content screening with our human library of microRNA inhibitors in primary prostate cancer cells extracted from patients.

Read full story...

Amy Hansen

Viral microRNAs Involved in Cell Reprogramming


"Previously, we had tried other inhibitor designs but these gave inconclusive results."

Amy Hansen is a Ph.D student at the University College London. She works in the Cancer Research UK Viral Oncology Group lead by Professor Chris Boshoff, Director of the UCL Cancer Institute.

Read full story...

Annick Harel-Bellan

MicroRNAs and Muscle Cell Differentiation


LNA microRNA antisense inhibitors are efficient and specific with long lasting effects.

Dr. Annick Harel-Bellan (AHB) is Directeur de Recherche at the Institut Andre Lwoff in Paris. She heads a group working on epigenetics and cancer (Laboratoire Epigenetique et Cancer). Dr. Anna Polesskaya (AP) is a senior scientist and longstanding member of this group.

Read full story...

This is a custom LNA™ product. Please contact us for further information and ordering.
Our global technical support team will respond within 2 business days.
 
  Privacy   Sitemap   Legal